Bivatuzumab
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| (verify) | |
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]
It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer.[1]
It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
References
- Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, et al. (October 2003). "Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer". Journal of Nuclear Medicine. 44 (10): 1690–9. PMID 14530488.
- Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA (September 2003). "Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma". Clinical Cancer Research. 9 (10 Pt 2): 3961S–72S. PMID 14506195.
- "Amendments to Previous Lists". WHO Drug Information. 16 (3). 2002.
- "Recommended INN: List 45" (PDF). WHO Drug Information. 15 (1): 4. 2001.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.